Skip to main content

Table 9 Results of subgroup analysis and interaction analysis

From: Association between hemoglobin and chronic kidney disease progression: a secondary analysis of a prospective cohort study in Japanese patients

Characteristic

participants

HR (95%CI) P for interacion

β(95%CI) P for interacion

Age(years)

 

0.6636

0.5920

  < 60(years)

218

0.859 (0.747, 0.988)

-0.308 (-0.881, 0.264)

  ≥ 60(years)

744

0.829 (0.751, 0.914)

-0.466 (-0.831, -0.102)

Gender

 

0.8543

0.6664

 Male

670

0.844 (0.766, 0.930)

-0.480 (-0.868, -0.092)

 Female

292

0.831 (0.722, 0.956)

-0.304 (-1.026, 0.417)

Urinary occult blood

 

0.1975

0.5015

 No

652

0.874 (0.786, 0.972)

-0.380 (-0.760, -0.001)

 Yes

310

0.788 (0.697, 0.892)

-0.566 (-1.080, -0.052)

BMI(kg/m2)

 

0.5280

0.1642

  < 23.5

492

0.825 (0.737, 0.924)

-0.715 (-1.168, -0.262)

  ≥ 23.5

470

0.866 (0.775, 0.968)

-0.304 (-0.752, 0.144)

SBP(mmHg)

 

0.0276

0.3823

  < 140

514

0.741 (0.651, 0.843)

-0.317 (-0.740, 0.107)

  ≥ 140

448

0.871 (0.791, 0.959)

-0.536 (-0.961, -0.111)

UPCR (g/gCr)

 

0.0145

0.2201

  < 0.5

458

0.683 (0.548, 0.851)

-0.217 (-0.742, 0.308)

  ≥ 0.5

504

0.903 (0.832, 0.981)

-0.637 (-1.075, -0.199)

Etiology of CKD

 

0.3714

0.9391

 Diabetic nephropathy

44

0.781 (0.692, 0.881)

-0.498 (-1.049, 0.053)

 Nephrosclerosis

85

0.943 (0.786, 1.130)

-0.391 (-0.846, 0.064)

 Glomerulonephritis

178

0.799 (0.605, 1.055)

-0.566 (-1.227, 0.096)

 Other

155

0.868 (0.613, 1.230)

-0.338 (-0.990, 0.314)

Use of RAAS inhibitor

 

0.9565

0.7207

 No

336

0.830 (0.712, 0.967)

-0.496 (-0.974, -0.018)

 Yes

626

0.834 (0.761, 0.913)

-0.404 (-0.789, -0.018)

Hypertension

 

0.0173

0.6052

 No

96

0.435 (0.257, 0.734)

-0.716 (-1.657, 0.225)

 Yes

866

0.842 (0.775, 0.915)

-0.457 (-0.823, -0.091)

History of CVD

 

0.0978

0.1901

 No

704

0.862 (0.787, 0.944)

-0.323 (-0.706, 0.059)

 Yes

258

0.755 (0.652, 0.874)

-0.694 (-1.212, -0.175)

Diabetes

 

0.7648

0.1948

 No

598

0.819 (0.728, 0.922)

-0.592 (-1.005, -0.179)

 Yes

364

0.837 (0.759, 0.923)

-0.208 (-0.697, 0.280)

Use of calcium channel blocker

 

0.2353

0.7644

 No

503

0.791 (0.698, 0.897)

-0.474 (-0.901, -0.047)

 Yes

459

0.869 (0.783, 0.965)

-0.398 (-0.821, 0.024)

Use of diuretics

 

0.0271

0.3428

 No

650

0.903 (0.811, 1.005)

-0.615 (-1.010, -0.220)

 Yes

312

0.761 (0.676, 0.856)

-0.329 (-0.854, 0.195)

ALB(g/dL)

 

0.8595

0.1032

 < 4

465

0.837 (0.768, 0.911)

-0.716 (-1.129, -0.303)

  ≥ 4

497

0.852 (0.711, 1.021)

-0.280 (-0.718, 0.159)

  1. Note 1:Above model adjusted for age, gender, BMI, SBP, hypertension, diabetes, history of CVD, UPCR, eGFR, ALB, urinary occult blood, use of RAAS inhibitor, use of calcium channel blocker, and use of diuretics
  2. Note 2:In each case, the model is not adjusted for the stratification variable